Condition: Carcinoma, Hepatocellular · Sponsor: Shanghai Henlius Biotech
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of Serplulimab Injection (HLX10, a Recombinant Anti-PD-1 Antibody) and HLX04 (a Biosimilar to Bevacizumab) With or Without HLX53 (an Anti-TIGIT Fc Fusion Protein) in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
This description comes directly from the study's public registry record.
Jia Fan, Dr · 021-64041990 · fan.jia@zs-hospital.sh.cn
Huichuan Sun, Dr · sun.huichuan@zs-hospital.sh.cn
Always discuss trial participation with your own doctor first.
| Zhongshan Hospital, Fudan University | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06349980